Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Overview Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Companies Involved in Therapeutics Development Aclaris Therapeutics Inc Arrien Pharmaceuticals LLC Corvus Pharmaceuticals Inc Genentech Inc Japan Tobacco Inc Novartis AG Principia Biopharma Inc Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Drug Profiles ARN-4079 - Drug Profile Product Description Mechanism Of Action R&D Progress GNE-4997 - Drug Profile Product Description Mechanism Of Action R&D Progress JTE-051 - Drug Profile Product Description Mechanism Of Action R&D Progress pazopanib hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress pazopanib hydrochloride + pembrolizumab - Drug Profile Product Description Mechanism Of Action R&D Progress PRN-694 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit ITK and TXK for Psoriasis and Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit ITK for Autoimmune Disorders, Chronic Inflammation and Colorectal Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit ITK for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Dormant Products Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Discontinued Products Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Product Development Milestones Featured News & Press Releases Jul 21, 2016: Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer Mar 16, 2015: Cancer drug may reduce bleeding in patients with rare genetic disorder, HHT Sep 01, 2014: Arrien Pharmaceuticals Provides Update on ARN-4079 Apr 01, 2014: Results from phase III patient preference study of GSK’s Votrient (pazopanib) vs. Sutent (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology Mar 31, 2014: Votrient as maintenance therapy for advanced ovarian cancer in the EU Aug 21, 2013: Pazopanib shows better quality-of-life in advanced kidney cancer Aug 07, 2013: GSK seeks additional indication approval for Votrient from EMA Jul 11, 2013: GlaxoSmithKline's cancer drug Votrient receives full EU approval Jun 01, 2013: GSK's Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintenance Therapy In Women With Advanced Epithelial Ovarian Cancer Jan 08, 2013: Combination Of Pazopanib And Paclitaxel May Slow Anaplastic Thyroid Cancer, Mayo Clinic Study Shows Oct 01, 2012: GlaxoSmithKline's Votrient Meets Primary Endpoint In Pivotal Phase III Study Of Advanced Renal Cell Carcinoma Aug 07, 2012: GlaxoSmithKline Receives Marketing Authorization From European Commission For Pazopanib May 25, 2012: GSK Receives Positive Opinion From European CHMP For Pazopanib In Treatment Of Patients With Certain Advanced Soft Tissue Sarcomas Apr 26, 2012: GSK's Votrient Receives FDA Approval For Treatment Of Advanced Soft Tissue Sarcoma Mar 20, 2012: GSK Announces Positive Vote From FDA Panel For Pazopanib In Certain Advanced Soft Tissue Sarcomas Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indications, H2 2017 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Aclaris Therapeutics Inc, H2 2017 Pipeline by Arrien Pharmaceuticals LLC, H2 2017 Pipeline by Corvus Pharmaceuticals Inc, H2 2017 Pipeline by Genentech Inc, H2 2017 Pipeline by Japan Tobacco Inc, H2 2017 Pipeline by Novartis AG, H2 2017 Pipeline by Principia Biopharma Inc, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Discontinued Products, H2 2017 List of Figures Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Top 10 Indications, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

Aclaris Therapeutics Inc Arrien Pharmaceuticals LLC Corvus Pharmaceuticals Inc Genentech Inc Japan Tobacco Inc Novartis AG Principia Biopharma Inc